2016
DOI: 10.1007/s11864-015-0385-x
|View full text |Cite
|
Sign up to set email alerts
|

Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis

Abstract: Adequate surgical resection remains the treatment of choice for tenosyovial giant cell tumor (TGCT). However, diffuse type TGCT (D-TGCT) is more difficult to resect and has a higher rate of recurrence (up to 50 %), which is often multiple. D-TGCT is rarely lethal and only rare cases of metastases have been described. Nevertheless, patients might have a significant decline in their quality of life due to multiple operations, which may sometimes result in a partial loss of function of the affected joint and may … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
106
0
2

Year Published

2016
2016
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 103 publications
(109 citation statements)
references
References 36 publications
1
106
0
2
Order By: Relevance
“…High expression levels of CSF1R were associated with higher lung cancer-specific mortality [69]. CSF1R and PTPRC are known to regulate a variety of cellular processes including cell growth, differentiation, and oncogenic transformation [70]. The present study is the first to identify the prognostic significance of these three genes, which may serve as valuable prognostic indicators of TGCT.…”
Section: Ppimentioning
confidence: 68%
“…High expression levels of CSF1R were associated with higher lung cancer-specific mortality [69]. CSF1R and PTPRC are known to regulate a variety of cellular processes including cell growth, differentiation, and oncogenic transformation [70]. The present study is the first to identify the prognostic significance of these three genes, which may serve as valuable prognostic indicators of TGCT.…”
Section: Ppimentioning
confidence: 68%
“…Clinical trials conducted by Roche using CSF1R monoclonal antibody (RG7155) therapy were successful in depleting TAMs from the tumor tissue 24,32 . Importantly, targeting TAMs via the CSF1/CSF1R axis was efficacious and resulted in improvement of patients.…”
Section: Discussionmentioning
confidence: 99%
“…The CSF1 recruits nonneoplastic cells, including macrophages and monocytes, thus forming a tumor mass [3][4][5] . Currently, CSF1 receptor inhibitors have shown clinical activity in trials for the treatment of TSGCT [6] .…”
Section: Introductionmentioning
confidence: 99%